Relypsa’s Veltassa Dodges the Competition Bullet as FDA Hands AstraZeneca a Second Complete Response Letter for Hyperkalemia Agent, ZS-9

Delay gives Relypsa time to close the nephrology-to-cardiology gap for Veltassa Download Report Overview March 20, 2017 – Cambridge, Massachusetts. Sixteen months and $2.7 billion ago, ZS Pharma’s hyperkalemia candidate (ZS-9, sodium zirconium cyclosilicate) was one of the most highly anticipated drugs in the renal market.  Since being acquired by AstraZeneca, the company last week

The Battle for Preferred Alternative Mechanism Biologic in Crohn’s Disease Heats Up as Launch of Janssen’s Stelara Approaches the Six-Month Mark

While gastroenterologists report a strong intent to increase future prescribing, they are quite divided about whether Stelara will displace Takeda’s Entyvio as the alternate mechanism share leader, according to the latest report by Spherix Global Insights Download Report Overview March 20, 2017 – Cambridge, Massachusetts. Spherix Global Insights has released “RealTime Dynamix: Crohn’s Disease, Q1

Will US Rheumatologists Follow in the Footsteps of Dermatologists for Adoption of Eli Lilly’s Taltz?

CAMBRIDGE, Mass., Jan. 26, 2017 /PRNewswire/ -- A recent study of 100 surveyed US rheumatologists, reveals that after viewing a product profile for the likely second to market IL-17 inhibitor for PsA, 84% anticipate prescribing Lilly's Taltz (ixekizumab), if approved. Furthermore, the vast majority of rheumatologists plan to initiate treatment within the first-year of launch.

Extended FDA Review for Lilly/Incyte’s Olumiant (baricitinib) in Rheumatoid Arthritis Delays Market Entry for First Major Competitor to Pfizer’s Xeljanz

And Sanofi-Regeneron’s IL-6 inhibitor, sarilumab, also getting back on track after receiving a Complete Response Letter from the FDA in October 2016. The competition to be the preferred first-line, non-TNF agent in the treatment RA is expected to be fierce in 2017, according to a new report from Spherix Global Insights Cambridge, Massachusetts. (PRWEB) January

Studies of the Multiple Sclerosis (MS) Market Highlight the Increasing Penetration of Oral Disease-modifying Therapies (DMTs) into First Line Position

ZUG, Switzerland, Jan. 17, 2017 /PRNewswire/ -- The MS market has shifted over the course of 2016 according to the Q4 update of RealTime Dynamix™, an independent report based on survey responses of 100 US neurologists who actively manage patients with MS. According to the study, oral DMTs captured a significantly higher share at the